Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

NeuBase Therapeutics Inc (NBSE) USD0.0001

Sell:$7.05 Buy:$7.19 Change: $0.24 (3.49%)
Market closed |  Prices as at close on 11 December 2019 | Switch to live prices |
Change: $0.24 (3.49%)
Market closed |  Prices as at close on 11 December 2019 | Switch to live prices |
Change: $0.24 (3.49%)
Market closed |  Prices as at close on 11 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NeuBase Therapeutics, Inc., formerly Ohr Pharmaceutical, Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company's development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine, also known as OHR-102), SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company's animal model for dry-AMD, mice are immunized with a carboxyethylpyrrole, which is bound to mouse serum albumin.

Contact details

700 Technology Dr
United States
+1 (646) 4501790

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$116.59 million
Shares in issue:
17.07 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Dietrich Stephan
    President, Chief Executive Officer, Director
  • Sam Backenroth
    Chief Financial Officer, Treasurer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.